Avanos (AVNS) Q4 2022: $35M Product Exit Signals Portfolio Overhaul and Margin Ambition
Avanos’ decisive $35 million product portfolio rationalization marks a strategic pivot toward higher-margin categories and operational discipline. Management’s transformation plan, including cost-outs and a focus on core growth platforms, aims to boost profitability and free cash flow despite ongoing supply chain and reimbursement headwinds. Investors should watch for execution on cost savings and M&A to realize the promised margin expansion and capital deployment.
Summary
- Portfolio Exit Reshapes Focus: Avanos is exiting $35 million in low-profit categories to redirect resources to core growth areas.
- Cost Transformation Underway: $10 million in 2023 cost savings will accelerate margin uplift and fund reinvestment.
- Margin Expansion Targets: Management signals EBITDA margin ambitions above 22% within three years, hinging on execution and discipline.
Business Overview
Avanos is a medical technology company specializing in chronic care and pain management solutions. The business generates revenue through a mix of consumable medical devices and specialty therapies, with major segments including digestive health (feeding tubes, neonatal products), respiratory health (closed suction catheters), and pain management (acute and interventional pain products including OrthoGenerex, orthopedic pain therapy). The company also leverages targeted M&A to expand its portfolio and drive growth in higher-margin categories.
Performance Analysis
Fourth quarter results reflected strong top-line growth, with reported sales up double digits and organic growth in the mid-single digits after adjusting for foreign exchange. Digestive health led the way, posting over 10% growth, and Neomed, neonatal enteral feeding technology, delivered nearly 40% expansion. The pain management segment posted modest growth, with interventional pain up mid-single digits, while acute pain grew low single digits. Respiratory business contracted, but closed suction catheters rebounded with 8% growth, aided by seasonal pediatric demand.
Gross margin improved sharply by 450 basis points for the year, reaching 56.8%, driven by favorable product mix and manufacturing efficiency initiatives. Free cash flow generation was robust despite backorder challenges, with $29 million delivered in Q4 and $72 million for the year. These gains were partially offset by elevated supply chain costs and backorders, which rose to nearly $10 million early in 2023, primarily in digestive health. SG&A discipline held, with full-year spend below 39% of revenue, supporting margin expansion.
- Digestive Health Outperformance: Neomed’s 40% growth and strong NFIT conversions highlight Avanos’ leadership in neonatal safety feeding technology.
- Product Rationalization Impact: The exit of low-margin products will reduce annualized revenue by $35 million but is expected to be margin accretive.
- Cost Discipline Drives Margin: Operating leverage from SG&A containment and manufacturing efficiency underpins the transformation thesis.
While management delivered on revenue, margin, and free cash flow targets, execution on portfolio pruning and cost-out will be the key lever for future value creation.
Executive Commentary
"These results position us to confidently execute against the transformation priorities we laid out at the J.P. Morgan Conference in January... Our primary objectives were centered around consistent organic growth, delivering on our OrthoGenerex strategy, making meaningful improvements in our gross margin profile, and demonstrating our ability to deliver material-free cash flow."
Joe Woody, Chief Executive Officer
"Our transformation priorities are designed to shift our product portfolio over time into a higher growth portfolio leveraging our cornerstone product families in digestive health and interventional pain. Additionally, these priorities are aimed at right-sizing our cost structure and enhancing our operating profitability with EBITDA margins ultimately exceeding 22% while generating annual free cash flow of $100 million."
Michael Greiner, CFO and Chief Transformation Officer
Strategic Positioning
1. Portfolio Rationalization and Exit of Low-Margin Products
Avanos is exiting select acute pain and smaller product categories with insufficient profitability, resulting in an annualized revenue loss of $35 million. This move is intended to sharpen focus on core platforms and drive margin accretion, with most exits expected to be completed in 2023. The company will provide more detail at its June Investor Day, but the strategy signals a willingness to walk away from unprofitable volume in favor of sustainable, higher-return growth.
2. Transformation Program and Cost Reduction
Management is targeting $10 million in cost savings for 2023, ramping to $45–55 million by 2025, via outsourcing, third-party contract rebidding, role eliminations, and SG&A optimization. The transformation is not simply a cost-takeout exercise but a portfolio optimization effort, aiming to redeploy resources into growth segments and improve operating leverage.
3. Core Growth Engines: Digestive Health and Interventional Pain
Digestive health and interventional pain are positioned as Avanos’ “right to win” categories. Neomed’s strong performance and ongoing NFIT conversion cycle provide a durable growth runway, though management notes the conversion is entering later innings. Interventional pain, especially through the OrthoGenerex platform, is expected to benefit from pricing discipline and expanded patient access programs.
4. M&A and Capital Deployment Discipline
Despite disappointment in not closing additional deals in 2022, management remains active in pursuing tuck-in M&A, with a robust pipeline focused on digestive health and orthopedic pain. The company’s leverage ratio below one times and $128 million in cash on hand provide ample capacity for strategic acquisitions that fit the new portfolio focus.
5. Supply Chain and Backorder Management
Supply chain headwinds persist, particularly in digestive health due to Tyvek shortages and supplier constraints. Management expects these issues to abate by Q3 2023, which should support more consistent revenue conversion and inventory normalization.
Key Considerations
Avanos’ transformation is a multi-year journey with significant moving parts. The company’s willingness to exit unprofitable businesses, invest in core growth platforms, and drive cost discipline is a positive signal, but execution risk remains high given ongoing supply chain volatility and reimbursement pressures.
Key Considerations:
- Portfolio Focus Sharpens: Exiting low-margin categories will test Avanos’ ability to offset lost sales with higher-margin growth and operational efficiency.
- Cost Savings Timeline: Most of the $45–55 million in targeted savings will materialize in 2024, making 2023 a transition year with uneven pacing.
- Margin Expansion Path: EBITDA margin exited Q4 at 20.8%, with a goal to exceed 22% by 2025, but this depends on successful execution of cost and portfolio initiatives.
- M&A Execution: A robust deal pipeline could accelerate top-line growth and platform strength, but integration and valuation discipline are critical.
- Supply Chain Drag: Backorders, particularly in digestive health, remain a near-term drag but are expected to ease by the second half of 2023.
Risks
Execution on transformation and cost-out is critical, with risks around the timing and realization of savings, as well as the ability to drive organic growth in the absence of exited product revenue. Supply chain disruptions and reimbursement volatility could pressure margins and slow recovery. M&A integration and overpayment risk also loom, given the company’s stated ambition to deploy capital for growth. Management’s guidance assumes no material macroeconomic deterioration or new regulatory hurdles.
Forward Outlook
For Q1 2023, Avanos expects:
- A slow start to the year, with acceleration in the back half as supply chain and cost initiatives take hold.
- Organic revenue growth in the low single digits, reflecting the $35 million product exit impact.
For full-year 2023, management guided to:
- Adjusted diluted EPS of $1.60 to $1.80
- At least $60 million in free cash flow, excluding $20–25 million in restructuring costs
- EBITDA and operating margin improvement of at least 100 basis points
Management highlighted that gross margin should remain sticky at or above 57% and SG&A should trend lower as a percentage of revenue. The company expects to provide more granular transformation details and updated targets at its June Investor Day.
- Transformation savings will be back half weighted.
- Supply chain normalization and portfolio exits will drive sequential improvement.
Takeaways
Avanos’ Q4 marks a strategic inflection point as management commits to portfolio discipline, margin expansion, and operational focus.
- Portfolio Overhaul: The $35 million product exit is a clear signal that Avanos is prioritizing profitability and focus over volume, with management willing to absorb near-term revenue loss for long-term value creation.
- Transformation Execution: Delivering the promised cost savings and margin expansion will be the key test in 2023 and 2024, especially as supply chain and reimbursement headwinds persist.
- Growth Engine Reliance: Core platforms in digestive health and interventional pain must deliver consistent organic growth to offset divested or exited revenue and justify the company’s capital allocation strategy.
Conclusion
Avanos enters 2023 with a bold transformation agenda and credible financial discipline, but faces a transition year marked by portfolio exits and supply chain friction. Margin expansion and free cash flow generation are within reach if execution remains disciplined, and the June Investor Day will be a key milestone for investor confidence.
Industry Read-Through
Avanos’ willingness to walk away from low-margin categories and double down on core platforms reflects a broader medtech trend toward portfolio focus and margin discipline. The move to rationalize SKUs and optimize cost structure is likely to be echoed by peers facing similar supply chain and inflationary pressures. Strong growth in neonatal and digestive health technologies, such as Neomed, highlights demand for safety and innovation in pediatric care, while pricing discipline in pain management signals a more selective approach to reimbursement volatility. Investors should watch for similar transformation playbooks across the sector, especially among mid-cap medtechs seeking to balance growth and profitability in a challenging macro environment.